Administer by slow intravenous injection (1 mL/minute to avoid hypotension) or as a continuous intravenous infusion. Do not administer intramuscularly.

Tranexamic acid competitively inhibits the activation of plasminogen to plasmin. Plasmin is an enzyme responsible for the degradation of fibrin clots, a process called fibrinolysis. By blocking plasmin, tranexamic acid stabilizes the clot and prevents its premature breakdown, thereby reducing bleeding.

• •Active intravascular clotting
• •Subarachnoid hemorrhage (risk of cerebral edema and infarction)
• •Severe renal impairment (risk of accumulation)
• •History of convulsions
• •Hypersensitivity to tranexamic acid

Store below 30°C. Protect from light. Do not freeze.

Symptoms may include nausea, vomiting, diarrhea, orthostatic hypotension, headache, dizziness, and convulsions. Management is supportive and symptomatic, with appropriate fluid replacement and monitoring of vital signs. Hemodialysis is not very effective.

Pregnancy Category B. Use only if clearly needed. Excreted into breast milk, but in amounts unlikely to affect the infant. Use with caution in nursing mothers.